会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • IDENTIFICATION OF THERAPEUTIC AGENTS EFFECTIVE AGAINST INFECTION BY MEMBERS OF THE PARASITE FAMILY TRYPANOSOMATIDAE
    • 鉴定有效防治寄生虫寄生虫成虫的治疗药物
    • WO1994028162A1
    • 1994-12-08
    • PCT/US1994005624
    • 1994-05-19
    • NORTHEASTERN UNIVERSITY
    • NORTHEASTERN UNIVERSITYSTRAUSS, Phyllis, R.
    • C12Q01/00
    • C12Q1/18C12Q1/34
    • DNA polymerase beta isolated from a member of the parasite family Trypanosomatidae, the species Trypanosoma brucei, has been determined to be the primary drug target for the trypanocidal agent berenil (diminazene aceturate), being four orders of magnitude more sensitive to the drug than is either human DNA polymerase beta or alpha . DNA polymerases of the alpha family isolated from T. brucei, also effective targets of berenil, are two orders of magnitude more sensitive than either of the human enzymes. The discovery of the differential sensitivity of the DNA polymerases from T. brucei to a trypanocidal agent has permitted the development of methods for systematically identifying and using therapeutic agents effective in treating a patient suffering from an infection by a member of this family of parasites. The methods include testing the sensitivity of DNA polymerase alpha and DNA polymerase beta from a member of the family Trypanosomatidae to a candidate trypanocidal agent, comparing the determined sensitivity of the DNA polymerases to the candidate agent, and testing the DNA polymerase having greater sensitivity against decreasing levels of the candidate agent. In this way a minimal effective dosage of the agent can be determined.
    • 从寄生虫家族Trypanosomatidae(Brypanosoma trypanosoma brucei)的成员中分离的DNA聚合酶β已被确定为杀虫剂be il(二亚胺乙酸酯)的主要药物靶标,比药物更敏感4个数量级 人类DNA聚合酶β或α。 从布鲁氏菌中分离出来的α家族的DNA聚合酶也是贝尼尔的有效靶标,比人类酶的敏感性高两个数量级。 发现从布鲁斯布氏锥虫病到杀虫剂的DNA聚合酶的差异敏感性允许开发用于系统地鉴定和使用治疗剂的方法,所述治疗剂有效地治疗患有该寄生虫家族的感染的患者。 这些方法包括测试DNA聚合酶α和DNA聚合酶β从锥虫科科的成员对候选的杀虫剂的敏感性,比较确定的DNA聚合酶对候选试剂的敏感性,并测试具有较高灵敏度降低的DNA聚合酶 候选人的级别。 以这种方式,可以确定药剂的最小有效剂量。
    • 10. 发明申请
    • QUANTIFYING TRACE ANALYTES BY AFFINITY CAPILLARY ELECTROPHORESIS
    • 定量毛细管电泳分析痕量分析
    • WO1994017409A1
    • 1994-08-04
    • PCT/US1994000426
    • 1994-01-12
    • NORTHEASTERN UNIVERSITY
    • NORTHEASTERN UNIVERSITYKARGER, Barry, L.SHIMURA, Kiyohito
    • G01N33/561
    • G01N27/44795G01N27/44726G01N33/533G01N33/561G01N33/6857
    • A method for quantitative detection of trace amounts of an analyte in a sample is disclosed. The method in the preferred embodiment includes providing an Fab' fragment of an immunoglobulin labelled at a reactive sulfhydryl group with a fluorescent dye; combining the labelled Fab' fragment with a sample that may contain the analyte; concentrating the elements of the resulting mixture in an electric field; separating the labelled analyte/agent complex formed from any unreacted labelled agent using capillary electrophoretic methods; and detecting the fluorescent signal of the labelled analyte/agent complex. The invention also is directed to a method of producing a labelled Fab' fragment that includes cleaving an immunoglobulin molecule to obtain one F(ab')2 fragment; reducing the disulfide-bonds of the F(ab')2 fragment to obtain two Fab' fragments each having at least one free, reactive sulfhydryl group; and mixing an Fab' fragment having at least one free sulfhydryl group with a fluorescent dye reactive with the free sulfhydryl to form a labelled Fab' fragment. Preferably, prior to the final mixing step, intrastrand disulfide bonds are formed by oxidation within each Fab' fragment, thereby producing individual Fab' fragments each having a single reactive sulfhydryl group. The method of quantitative detection also more broadly includes using any biospecific agent to form a complex with the target analyte.
    • 公开了一种用于定量检测样品中微量分析物的方法。 优选实施方案中的方法包括提供在反应性巯基上标记的免疫球蛋白的Fab'片段与荧光染料; 将标记的Fab'片段与可以含有分析物的样品结合; 将所得混合物的元素集中在电场中; 使用毛细管电泳方法分离由任何未反应的标记试剂形成的标记分析物/试剂络合物; 并检测标记的分析物/试剂复合物的荧光信号。 本发明还涉及产生标记的Fab'片段的方法,其包括切割免疫球蛋白分子以获得一个F(ab')2片段; 减少F(ab')2片段的二硫键,得到两个具有至少一个游离的反应性巯基的Fab'片段; 并将具有至少一个游离巯基的Fab'片段与与游离巯基反应的荧光染料混合以形成标记的Fab'片段。 优选地,在最终混合步骤之前,通过在每个Fab'片段内的氧化形成原子间二硫键,由此产生各自具有单个反应性巯基的单个Fab'片段。 定量检测的方法也更广泛地包括使用任何生物特异性试剂与靶分析物形成复合物。